RxDoctor Payments DataLook up a doctor →

Matthew Becker, MD

Interventional Cardiology · Erie, PANPI 1598932550

Payments from drug & device makers

$1,314,862in general payments, 2019–2025

Across 1,400 payments — averaging $939.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$587K
  • W. L. Gore & Associates, Inc.$134K
  • Amgen$109K
  • Boston Scientific$104K
  • Contego Medical, Inc$100K
  • Inari Medical, Inc.$73K
  • plus $206K from 40 others

What the payments were for

  • Consulting fees$156,67315%
  • Speaking & faculty fees$753,32972%
  • Travel & lodging$65,2516%
  • Food & beverage$28,9313%
  • Education$80%
  • Other$36,3753%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,314,862 in reported general payments places this provider in the 95th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$125,117
Medicare patients
280
Services billed
753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban114$94,064
JardianceEmpagliflozin50$41,081
EntrestoSacubitril/Valsartan41$36,967
Repatha SureclickEvolocumab43$30,572
EliquisApixaban26$24,145
VerquvoVericiguat28$21,268
BrilintaTicagrelor32$19,862
Ranolazine ErRanolazine46$3,166
Metoprolol Succinate84$800
Losartan Potassium43$632
Atorvastatin Calcium63$471
ClopidogrelClopidogrel Bisulfate58$408
Isosorbide Mononitrate ErIsosorbide Mononitrate28$390
Amlodipine Besylate49$216
Rosuvastatin Calcium18$197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$587,156$94,064114 claims
Boehringer IngelheimJardiance$79$41,08150 claims
NovartisEntresto$33,512$36,96741 claims
PfizerEliquis$15$24,14526 claims
MerckVerquvo$148$21,26828 claims
AstraZenecaBrilinta$140$19,86232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →